CBS 2019
CBSMD教育中心
中 文

双重抗血小板治疗持续时间

Abstract

Recommended Article

Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI A Genotype-Guided Strategy for Oral P2Y12 Inhibitors in Primary PCI 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines Clopidogrel Pharmacogenetics: State-of-the-Art Review and the TAILOR-PCI Study Patient Selection and Clinical Outcomes in the STOPDAPT-2 Trial: An All-Comer Single-Center Registry During the Enrollment Period of the STOPDAPT-2 Randomized Controlled Trial 6-Month Versus 12-Month Dual-Antiplatelet Therapy Following Long Everolimus-Eluting Stent Implantation: The IVUS-XPL Randomized Clinical Trial Derivation, Validation, and Prognostic Utility of a Prediction Rule for Nonresponse to Clopidogrel: The ABCD-GENE Score Safety of six-month dual antiplatelet therapy after second-generation drug-eluting stent implantation: OPTIMA-C Randomised Clinical Trial and OCT Substudy

Editorial01 July 2020

JOURNAL:Eur Heart J. Article Link

Identifying coronary artery disease patients at risk for sudden and/or arrhythmic death: remaining limitations of the electrocardiogram

B Asatryan, L Roten, T Reichlin et al. Keywords: sudden death; arrhythmic death; electrocardiogram; CHD

ABSTRACT

The important study concerning the easy-to-use electrocardiogram (ECG) markers of sudden and/or arrhythmic death (SAD) in coronary artery disease (CAD) patients as presented by Chatterjee et al.1 is a weighty contribution to an intricate and still rather puzzling topic. They implicate that in CAD patients, contiguous Q waves, left ventricular hypertrophy (LVH), QRS duration, and JTc prolongation provide incremental predictive value beyond traditional risk factors for SAD. While this study is unique in providing easily measurable markers that improve SAD risk stratification, it also...